4.1 Review

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms

Journal

MICROBIAL CELL
Volume 5, Issue 7, Pages 300-326

Publisher

SHARED SCIENCE PUBLISHERS OG
DOI: 10.15698/mic2018.07.638

Keywords

antifungal susceptibility testing; biofilm inhibition; biofilm eradication; antibiofilm material coating; in vivo models

Funding

  1. Industrial Research Fund [IOFm/05/022]
  2. European Research Council [3400867/RAPLODAPT]
  3. Israel Science Foundation [314/13]
  4. Wellcome Trust
  5. MRC
  6. Agence Nationale de Recherche [ANR-10-LABX-62-IBEID]
  7. National Institutes of Health [R35GM124594, R21AI125801]
  8. Wellcome Trust Strategic Award [097377]
  9. MRC Centre for Medical Mycology at the University of Aberdeen [MR/N006364/1]
  10. Astellas
  11. Basilea
  12. Gilead
  13. MSD
  14. NovaBiotics
  15. Pfizer
  16. T2Biosystems
  17. F2G
  18. Cidara
  19. Amplyx
  20. MRC [MR/N006364/1]
  21. FWO [FWO WO.009.16N]
  22. MRC [MR/N006364/1] Funding Source: UKRI

Ask authors/readers for more resources

Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available